See more : Corcel Plc (CRCL.L) Income Statement Analysis – Financial Results
Complete financial analysis of Basilea Pharmaceutica AG (BPMUF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Basilea Pharmaceutica AG, a leading company in the Biotechnology industry within the Healthcare sector.
- Vision Marine Technologies Inc. (VMAR) Income Statement Analysis – Financial Results
- Kokuyo Co., Ltd. (7984.T) Income Statement Analysis – Financial Results
- Stockland (SGP.AX) Income Statement Analysis – Financial Results
- Stamen Co.,Ltd. (4019.T) Income Statement Analysis – Financial Results
- Osceola Gold, Inc. (OSCI) Income Statement Analysis – Financial Results
Basilea Pharmaceutica AG (BPMUF)
About Basilea Pharmaceutica AG
Basilea Pharmaceutica AG, a commercial stage biopharmaceutical company, focuses on the development of products that address the medical needs in the therapeutic areas of oncology and anti-infectives. It offers Cresemba, an intravenous and oral azole antifungal drug for the treatment of invasive aspergillosis and mucormycosis in the United States, and the European Union, as well as in Phase III clinical trials for invasive fungal infections in Japan. The company also provides Zevtera, an antibiotic for the treatment of community and hospital-acquired pneumonia, as well as in Phase III clinical trials for the treatment of acute bacterial skin and skin structure infections, and Staphylococcus aureus bacteremia. In addition, it engages in developing Derazantinib, a small molecule inhibitor, which is in phase 2 clinical trial for bile duct cancer, as well as in phase ½ clinical trial for bladder and stomach cancer; and Lisavanbulin, a tumor checkpoint controller drug. Basilea Pharmaceutica AG was founded in 2000 and is headquartered in Basel, Switzerland.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 157.63M | 147.77M | 148.12M | 127.63M | 134.38M | 132.56M | 101.52M | 65.98M | 51.65M | 42.50M | 40.95M | 57.88M |
| Cost of Revenue | 26.79M | 24.60M | 24.07M | 24.05M | 18.87M | 20.30M | 9.03M | 5.35M | 60.08M | 54.38M | 53.35M | 63.26M |
| Gross Profit | 130.84M | 123.16M | 124.05M | 103.58M | 115.51M | 112.26M | 92.50M | 60.64M | -8.42M | -11.88M | -12.40M | -5.38M |
| Gross Profit Ratio | 83.00% | 83.35% | 83.75% | 81.15% | 85.96% | 84.69% | 91.11% | 91.90% | -16.30% | -27.95% | -30.28% | -9.30% |
| Research & Development | 77.85M | 73.80M | 93.16M | 97.41M | 102.66M | 104.94M | 53.49M | 48.45M | 60.08M | 70.08M | 53.35M | 58.86M |
| General & Administrative | 33.78M | 30.82M | 29.72M | 29.42M | 0.00 | 0.00 | 0.00 | 55.88M | 51.41M | 29.99M | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 30.82M | 29.72M | 29.42M | 30.05M | 0.00 | 0.00 | 200.00K | 300.00K | 100.00K | 0.00 | 0.00 |
| SG&A | 33.78M | 30.82M | 29.72M | 29.42M | 30.05M | 31.41M | 53.14M | 56.08M | 51.71M | 30.09M | 21.31M | 42.22M |
| Other Expenses | 0.00 | 852.00K | -1.24M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 111.64M | 102.35M | 121.04M | 124.99M | 131.18M | 136.35M | 106.63M | 104.53M | 111.78M | 30.01M | 20.89M | 46.66M |
| Cost & Expenses | 138.43M | 126.95M | 145.11M | 149.04M | 150.05M | 156.65M | 115.66M | 109.87M | 114.31M | 84.38M | 74.24M | 16.60M |
| Interest Income | 1.69M | 326.00K | 66.00K | 104.00K | 28.00K | 6.53M | 6.65M | 6.38M | 6.00K | 364.00K | 293.60K | 0.00 |
| Interest Expense | 11.20M | 9.85M | 8.15M | 7.59M | 6.42M | 6.55M | 6.68M | 6.41M | 154.00K | 54.00K | 0.00 | 291.26K |
| Depreciation & Amortization | 1.58M | 3.10M | 2.45M | 2.29M | 1.64M | 1.85M | 1.99M | 2.32M | 2.53M | 2.29M | 2.72M | 3.64M |
| EBITDA | 23.24M | 23.05M | 2.11M | -5.89M | -14.32M | -22.24M | -10.36M | -41.57M | -59.16M | -39.54M | -30.57M | -47.21M |
| EBITDA Ratio | 14.74% | 15.62% | 1.75% | -16.15% | -10.66% | -16.78% | -11.96% | -63.00% | -116.41% | -93.04% | -74.65% | -75.17% |
| Operating Income | 19.21M | 18.54M | 1.19M | -8.22M | -17.20M | -24.10M | -14.14M | -43.89M | -62.66M | -41.83M | -33.29M | -47.15M |
| Operating Income Ratio | 12.18% | 12.55% | 0.80% | -6.44% | -12.80% | -18.18% | -13.92% | -66.51% | -121.30% | -98.43% | -81.28% | -81.46% |
| Total Other Income/Expenses | -8.74M | -6.44M | -7.98M | -6.45M | -5.18M | -7.07M | -4.89M | -7.07M | -35.00K | 310.00K | 293.60K | -5.19M |
| Income Before Tax | 10.46M | 12.10M | -6.79M | -14.67M | -22.38M | -31.16M | -19.03M | -50.95M | -61.52M | -41.52M | -32.99M | -52.34M |
| Income Before Tax Ratio | 6.64% | 8.19% | -4.59% | -11.49% | -16.66% | -23.51% | -18.74% | -77.22% | -119.10% | -97.70% | -80.57% | -90.43% |
| Income Tax Expense | 10.00K | -45.00K | 37.00K | 55.00K | 40.00K | 192.00K | 334.00K | 333.00K | 83.00K | 26.00K | 27.30K | 693.70K |
| Net Income | 10.45M | 12.15M | -6.83M | -14.72M | -22.42M | -31.35M | -19.36M | -51.29M | -61.60M | -41.55M | -33.02M | -53.03M |
| Net Income Ratio | 6.63% | 8.22% | -4.61% | -11.53% | -16.69% | -23.65% | -19.07% | -77.73% | -119.26% | -97.76% | -80.63% | -91.63% |
| EPS | 0.86 | 1.02 | -0.58 | -1.43 | -2.08 | -2.89 | -1.79 | -5.07 | -6.09 | -4.17 | -3.40 | -5.53 |
| EPS Diluted | 0.86 | 1.02 | -0.58 | -1.43 | -2.08 | -2.89 | -1.79 | -5.07 | -6.09 | -4.17 | -3.40 | -5.53 |
| Weighted Avg Shares Out | 12.15M | 11.86M | 11.68M | 10.28M | 10.76M | 10.84M | 10.85M | 10.12M | 10.11M | 9.95M | 9.71M | 9.59M |
| Weighted Avg Shares Out (Dil) | 12.14M | 11.94M | 11.68M | 10.28M | 10.76M | 10.84M | 10.85M | 10.12M | 10.11M | 9.95M | 9.71M | 9.59M |
Is Basilea Pharmaceutica (BPMUF) Outperforming Other Medical Stocks This Year?
Basilea Pharmaceutica AG (BPMUF) CEO David Veitch on Q2 2022 Results - Earnings Call Transcript
Source: https://incomestatements.info
Category: Stock Reports